Other candidates able to target FXR have been examined in clinical trials (i.e. OCA, WAY-362450), showing positive results in the management of cholestatic liver diseases and metabolic syndrome [127], but the effects on thermogenesis and browning processes are still unexplored. Here, NR1H4 is linked to metabolic syndrome.